Brokers Set Expectations for Vor Biopharma Inc.’s FY2028 Earnings (NYSE:VOR)
Vor Biopharma Inc. (NYSE:VOR – Free Report) – Research analysts at HC Wainwright lowered their FY2028 EPS estimates for shares of Vor Biopharma in a research report issued to clients and investors on Friday, May 10th. HC Wainwright analyst S. Ramakanth now expects that the company will earn $0.71 per share for the year, down from their previous estimate of $0.85. HC Wainwright has a “Buy” rating and a $17.50 price target on the stock. The consensus estimate for Vor Biopharma’s current full-year earnings is ($1.34) per share.
A number of other analysts have also issued reports on the stock. JMP Securities reissued a “market outperform” rating and set a $12.00 target price on shares of Vor Biopharma in a research note on Friday, March 22nd. Oppenheimer restated an “outperform” rating and set a $15.00 price target (down previously from $17.00) on shares of Vor Biopharma in a research note on Thursday, March 21st. Stifel Nicolaus lowered their target price on Vor Biopharma from $15.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 21st. Finally, Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Vor Biopharma in a report on Friday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $13.50.
Get Our Latest Stock Analysis on Vor Biopharma
Vor Biopharma Stock Down 5.5 %
Shares of Vor Biopharma stock opened at $1.71 on Monday. The stock’s fifty day moving average is $1.95 and its two-hundred day moving average is $2.07. Vor Biopharma has a 52 week low of $1.62 and a 52 week high of $5.70.
Vor Biopharma (NYSE:VOR – Get Free Report) last issued its quarterly earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.10.
Institutional Investors Weigh In On Vor Biopharma
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VOR. SG Americas Securities LLC purchased a new stake in shares of Vor Biopharma during the third quarter worth about $37,000. Exchange Traded Concepts LLC grew its stake in Vor Biopharma by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 60,170 shares of the company’s stock valued at $135,000 after purchasing an additional 15,258 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Vor Biopharma by 4.0% in the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after purchasing an additional 69,436 shares during the period. Finally, Acadian Asset Management LLC acquired a new stake in Vor Biopharma during the 1st quarter valued at approximately $126,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.
Vor Biopharma Company Profile
Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.
Further Reading
Receive News & Ratings for Vor Biopharma Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Vor Biopharma and related companies with MarketBeat.com’s FREE daily email newsletter.
